Can smokers use HRT safely?

Whether HRT is appropriate for individuals who smoke depends on many personal health factors that cannot be assessed through website content alone. Current clinical guidelines do address this population specifically, and the form of estrogen used is a central consideration. A prescriber should evaluate individual cardiovascular history, smoking history, and symptom burden before recommending any approach.

Why smoking matters

According to current NAMS guidelines, smoking increases blood viscosity and causes endothelial damage, which raises the baseline risk of venous thromboembolism, cardiovascular disease, and stroke. Per published clinical guidelines, oral estrogen undergoes first-pass hepatic metabolism and increases clotting factors, compounding the thrombotic risk already elevated in people who smoke.

Why transdermal estrogen is preferred for smokers

• Patches, gels, and sprays bypass first-pass hepatic metabolism, so according to current NAMS guidelines, they are associated with substantially lower venous thromboembolism risk compared with oral estrogen tablets.
• Transdermal delivery maintains more stable estrogen levels, which per published clinical guidelines is considered preferable for individuals with cardiovascular risk factors.
• Major menopause societies recommend transdermal estrogen as the preferred route for women who smoke or who carry other thrombotic risk factors, per current NAMS guidelines.

What about progesterone?

According to current NAMS guidelines, women with an intact uterus require progestogen co-administration to protect the endometrium. Per published clinical guidelines, micronized progesterone does not meaningfully increase venous thromboembolism risk and is not considered to interact adversely with smoking-related cardiovascular risk in the way that oral estrogen does. If compounded micronized progesterone is considered, the following applies: Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

When HRT requires additional caution or specialist review

• Recent deep vein thrombosis or pulmonary embolism
• Active or recent stroke or myocardial infarction within the past year
• Uncontrolled severe hypertension

Per published clinical guidelines, even in higher-risk situations a specialist may consider low-dose transdermal estrogen, but the decision must be individualized based on a complete clinical assessment.

Practical considerations

• Transdermal estrogen is the route recommended by current guidelines for individuals who smoke, per current NAMS guidelines.
• The lowest effective dose should be used, as per FDA-approved prescribing information for estrogen products.
• Annual blood pressure monitoring and review of additional risk factors — including migraine with aura, personal or family history of clots, and lipid profile — is consistent with published clinical guidelines.
• Smoking cessation reduces overall cardiovascular risk, though per published clinical guidelines, cessation is not required before initiating HRT when transdermal estrogen is chosen.

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history, including smoking status, cardiovascular risk profile, and severity of menopausal symptoms.